DERMATA THERAPEUTICS, INC. Net Cash Provided by (Used in) Continuing Operations
DERMATA THERAPEUTICS, INC. (DRMA) reported Net Cash Provided by (Used in) Continuing Operations of $11.10 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-17.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:NetCashProvidedByUsedInContinuingOperations · last filed 2025-03-17
- DERMATA THERAPEUTICS, INC. net cash provided by (used in) continuing operations for the quarter ending 2024-12-31 was $2.90M, a 75.21% decline year-over-year.
- DERMATA THERAPEUTICS, INC. net cash provided by (used in) continuing operations for the quarter ending 2024-09-30 was $3.40M.
- DERMATA THERAPEUTICS, INC. net cash provided by (used in) continuing operations for the quarter ending 2024-06-30 was $2.10M, a 19.85% decline year-over-year.
- DERMATA THERAPEUTICS, INC. net cash provided by (used in) continuing operations for the quarter ending 2024-03-31 was $2.70M, a 206.82% increase year-over-year.
- DERMATA THERAPEUTICS, INC. net cash provided by (used in) continuing operations for fiscal 2024 was $11.10M.
- DERMATA THERAPEUTICS, INC. net cash provided by (used in) continuing operations for fiscal 2022 was -$6.40M.
- DERMATA THERAPEUTICS, INC. net cash provided by (used in) continuing operations for fiscal 2020 was -$792.01K.
| Period end | Net Cash Provided by (Used in) Continuing Operations 3 month | Net Cash Provided by (Used in) Continuing Operations 6 month | Net Cash Provided by (Used in) Continuing Operations 9 month | Net Cash Provided by (Used in) Continuing Operations 12 month | Net Cash Provided by (Used in) Continuing Operations 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $6.30M derived: sum of 2 quarters · filed 2025-03-17 | $8.40M derived: sum of 3 quarters · filed 2025-03-17 | $11.10M 10-K · filed 2025-03-17 | |
| 2024-09-30 | $3.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $5.50M derived: sum of 2 quarters · filed 2024-11-13 | $8.20M 10-Q · filed 2024-11-13 | $19.90M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2024-06-30 | $2.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $4.80M 10-Q · filed 2024-08-07 | $16.50M derived: sum of 3 quarters · filed 2024-11-13 | $7.70M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2024-03-31 | $2.70M 10-Q · filed 2024-05-15 | $14.40M derived: sum of 2 quarters · filed 2024-11-13 | $5.60M derived: sum of 3 quarters · filed 2024-11-13 | $8.22M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-12-31 | $11.70M derived: 10-Q 12 month − 10-Q 9 month · filed 2024-11-13 | $2.90M derived: sum of 2 quarters · filed 2024-11-13 | $5.52M derived: sum of 3 quarters · filed 2024-11-13 | $6.40M 10-Q · filed 2024-11-13 | -$6.40M 10-K · filed 2024-03-21 |
| 2023-09-30 | -$8.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$6.18M derived: sum of 2 quarters · filed 2023-11-09 | -$5.30M 10-Q · filed 2023-11-09 | ||
| 2023-06-30 | $2.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $3.50M 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $880.00K 10-Q · filed 2023-05-11 | ||||
| 2022-12-31 | -$6.40M 10-K · filed 2024-03-21 | $8.80M 10-K · filed 2023-02-21 | |||
| 2022-03-31 | $178.30K 10-Q · filed 2022-05-16 | $318.17K derived: sum of 2 quarters · filed 2023-05-11 | -$178.96K derived: sum of 3 quarters · filed 2023-05-11 | $249.62K derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $139.86K derived: 10-Q 12 month − 10-Q 9 month · filed 2023-05-11 | -$357.27K derived: sum of 2 quarters · filed 2023-05-11 | $71.31K derived: sum of 3 quarters · filed 2023-05-11 | $1.60M 10-Q · filed 2023-05-11 | $2.21M 10-K · filed 2022-03-28 |
| 2021-09-30 | -$497.13K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$68.55K derived: sum of 2 quarters · filed 2021-11-15 | $1.46M 10-Q · filed 2021-11-15 | $1.32M derived: sum of 4 quarters · filed 2022-05-16 | |
| 2021-06-30 | $428.58K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-09-27 | $1.96M 10-Q · filed 2021-09-27 | $1.82M derived: sum of 3 quarters · filed 2022-05-16 | $1.05M derived: sum of 4 quarters · filed 2022-05-16 | |
| 2021-03-31 | $1.53M 10-Q · filed 2022-05-16 | $1.39M derived: sum of 2 quarters · filed 2022-05-16 | $616.81K derived: sum of 3 quarters · filed 2022-05-16 | ||
| 2020-12-31 | -$139.66K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$911.88K derived: sum of 2 quarters · filed 2022-03-28 | -$792.01K 10-K · filed 2022-03-28 | ||
| 2020-09-30 | -$772.22K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$652.35K 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | $119.87K 10-Q · filed 2021-09-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |